. 2022 Oct 13;20(11):2494–2506. doi: 10.1111/jth.15884

TABLE 3.

Cost per reportable for a single result from single site (R.C.G.) compared with cost for a single DOAC reversal dose

Measurand	Number of tests per annum	Cost per reportable	DOAC reversal agent	Per dose reversal USD cost	Alternative reversal agent per dose (USD cost)
Heparin (UFH/LMWH)	1136	$13 ^a	NA	NA	NA
Dabigatran	43	$55	Idarucizumab	~$5000	NA
Apixaban	13	$197 ^a	Andexanet alfa	±$26 000 low dose ±$52 000 high dose ⁷⁹ , ^b	PCCs ±$5500 ⁷⁹
Rivaroxaban	72	$23 ^a	Andexanet alfa	±$26 000 low dose ±$52 000 high dose ⁷⁹ , ^b	PCCs ±$5500 ⁷⁹

Abbreviations: DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; NA: not applicable; PCC, prothrombin complex concentrates; UFH, unfractionated heparin; USD, US dollar.

^{^a}

Cost per reportable represents cost for a calendar year at a single testing site (R.C.G.) for calibrator and control costs, with relative anti‐FXa kit cost distributed based on percentage of use for a single commercial source. When combining the cost to perform all FXa assays, the cost per reportable is $16.

^{^b}

Recent data reports price for andexanet alfa around $12 000 for four vials of 200 mg. ⁸⁰